Clinical Utility of Residual Hearing in the Cochlear Implant Ear

Inclusion Criteria

• •1. Provision of signed and dated informed consent form.
• •2. Adults, males and females, ages 18 -79 who have a bilateral sensorineural hearing loss with postlingual onset.
• •3. Minimum of 30 days experience with appropriately fit binaural amplification (standardized National Acoustic Laboratories (NAL) fitting method) verified with real ear measurements within 5 dB SPL of targets.
• •4. Limited benefit from conventional amplification in the best aided condition as defined by test scores of:
• •1. The ear to implanted: Consonant-nucleus-consonant (CNC) words ≤ 60% or AzBio sentences (+10, +5 dB SNR ≤ 60% correct)
• •2. Contralateral ear: ≤ 80% on CNC words or AzBio sentences (+10, +5 dB SNR ≤ 80% correct)
• •5. Low frequency Pure Tone Average (PTA- 125, 250, 500 Hz) ≤ 55 dB HL in the ear to be implanted.
• •6. Severe to profound mid to high-frequency sensorineural hearing loss (threshold average of 1000, 2000, 3000, and 4000 Hz ≥75 dB HL) in the ear to be implanted.
• •7. Low frequency PTA ≤ 55 dB HL sloping to moderately severe to profound mid-to high frequency sensorineural hearing loss (threshold average of 1000, 2000, 3000, 4000 Hz ≥ 60 dB) in the contralateral ear.
• •8. Proficient in English.
• •9. Undergoing implantation with a current generation CI device from either Cochlear Limited or Advanced Bionics AG.
• •1. Cochlear Limited devices include: Nucleus CI612, CI622, CI632, CI624
• •2. Advanced Bionics AG devices include: HiFocus SlimJ, Mid-Scala
• •10. Stated willingness and ability to complete testing and all associated study visits.